Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Up 117.2% in June

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 126,421 shares, an increase of 117.2% from the June 15th total of 58,214 shares. Based on an average daily trading volume, of 76,377 shares, the days-to-cover ratio is presently 1.7 days. Currently, 5.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Intensity Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics during the 4th quarter valued at approximately $26,000. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics in the fourth quarter worth $41,000. State Street Corp increased its stake in shares of Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares during the last quarter. Legacy Advisors LLC bought a new stake in shares of Intensity Therapeutics in the fourth quarter worth $63,000. Finally, Mesirow Financial Investment Management Inc. raised its holdings in Intensity Therapeutics by 25.5% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after acquiring an additional 51,000 shares in the last quarter. 3.74% of the stock is currently owned by hedge funds and other institutional investors.

Intensity Therapeutics Stock Up 1.2%

NASDAQ:INTS traded up $0.06 on Thursday, reaching $4.90. The stock had a trading volume of 17,506 shares, compared to its average volume of 46,091. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $4.36 and a 200 day moving average of $6.41. The stock has a market cap of $13.24 million, a P/E ratio of -0.86 and a beta of 2.78. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.12. On average, research analysts predict that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen upgraded Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Finally, Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $37.50.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.